Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Lead-1 SU Study Group

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Lead-1 SU Study Group

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

779 Sitaatiot (Scopus)

Alkuperäiskieli	Englanti
Sivut	268-278
Julkaisu	Diabetic Medicine
Vuosikerta	26
Numero	3
Tila	Julkaistu - 2009
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

YK:n kestävän kehityksen tavoitteet

Tämä tuotos edistää seuraavia kestävän kehityksen tavoitteita:

SDG 3 – Hyvä terveys ja hyvinvointi

Pääsy asiakirjaan

https://pubmed.ncbi.nlm.nih.gov/19317822

Siteeraa tätä

@article{1c28429361bf4af99c0ba09c6353bde5,

title = "Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)",

author = "\{Lead-1 SU Study Group\} and M Marre and V Ilvesm{\"a}ki and J Shaw and M Br{\"a}ndle and WM Bebakar and Kamaruddin and J Strand and M Zdravkovic and Le, \{THI Td\} and S Colagiuri",

year = "2009",

language = "English",

volume = "26",

pages = "268--278",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley-Blackwell",

number = "3",

}

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). / Lead-1 SU Study Group.
julkaisussa: Diabetic Medicine, Vuosikerta 26, Nro 3, 2009, s. 268-278.

Tutkimustuotos: Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

AU - Lead-1 SU Study Group

AU - Marre, M

AU - Ilvesmäki, V

AU - Shaw, J

AU - Brändle, M

AU - Bebakar, WM

AU - Kamaruddin, null

AU - Strand, J

AU - Zdravkovic, M

AU - Le, THI Td

AU - Colagiuri, S

PY - 2009

Y1 - 2009

M3 - Article

SN - 0742-3071

VL - 26

SP - 268

EP - 278

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 3

ER -